AU2015256178B2 - Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer - Google Patents

Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer Download PDF

Info

Publication number
AU2015256178B2
AU2015256178B2 AU2015256178A AU2015256178A AU2015256178B2 AU 2015256178 B2 AU2015256178 B2 AU 2015256178B2 AU 2015256178 A AU2015256178 A AU 2015256178A AU 2015256178 A AU2015256178 A AU 2015256178A AU 2015256178 B2 AU2015256178 B2 AU 2015256178B2
Authority
AU
Australia
Prior art keywords
resveratrol
ursolic acid
administered
diabetes
res
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015256178A
Other languages
English (en)
Other versions
AU2015256178A1 (en
Inventor
Jacob JUNCO
Huiyun LIANG
Sara REYNA
Thomas J. Slaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Publication of AU2015256178A1 publication Critical patent/AU2015256178A1/en
Application granted granted Critical
Publication of AU2015256178B2 publication Critical patent/AU2015256178B2/en
Priority to AU2020203419A priority Critical patent/AU2020203419B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015256178A 2014-05-05 2015-05-05 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer Ceased AU2015256178B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203419A AU2020203419B2 (en) 2014-05-05 2020-05-25 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461988859P 2014-05-05 2014-05-05
US61/988,859 2014-05-05
PCT/US2015/029224 WO2015171598A1 (en) 2014-05-05 2015-05-05 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203419A Division AU2020203419B2 (en) 2014-05-05 2020-05-25 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Publications (2)

Publication Number Publication Date
AU2015256178A1 AU2015256178A1 (en) 2016-11-24
AU2015256178B2 true AU2015256178B2 (en) 2020-02-27

Family

ID=54392898

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015256178A Ceased AU2015256178B2 (en) 2014-05-05 2015-05-05 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
AU2020203419A Ceased AU2020203419B2 (en) 2014-05-05 2020-05-25 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203419A Ceased AU2020203419B2 (en) 2014-05-05 2020-05-25 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Country Status (6)

Country Link
US (7) US10155003B2 (enExample)
EP (1) EP3139910B1 (enExample)
JP (2) JP6716468B2 (enExample)
AU (2) AU2015256178B2 (enExample)
MY (1) MY181685A (enExample)
WO (1) WO2015171598A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015256178B2 (en) * 2014-05-05 2020-02-27 The Board Of Regents Of The University Of Texas System Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
WO2017080958A1 (en) * 2015-11-13 2017-05-18 Unilever Plc Composition for hair follicle growth
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
WO2019011293A1 (zh) 2017-07-13 2019-01-17 华东理工大学 靶向于pd-1的皂苷类化合物及其应用
EP3681507B8 (en) * 2017-09-13 2024-03-13 Emmyon, Inc. Ursolic acid morpholine and diethanolamine salts
US20250295615A1 (en) * 2021-11-18 2025-09-25 Board Of Regents, The University Of Texas System Combinations of curcumin and ursolic acid and uses thereof
KR102991532B1 (ko) * 2023-09-06 2026-07-20 바이오스펙트럼 주식회사 천연 화합물을 포함하는 비만 및/또는 대사성 질환의 예방 또는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269537A1 (en) * 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7772195B2 (en) * 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
CN101516364B (zh) * 2006-07-14 2011-12-28 帝斯曼知识产权资产管理有限公司 组合物及其用于治疗、共治疗或预防炎性病症的用途
SG178716A1 (en) * 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
CN101032564B (zh) * 2007-02-28 2011-03-23 天津津酒集团有限公司 调节血脂养生酒及其制备方法
WO2010095926A1 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
AU2011240690C1 (en) * 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
US9393221B2 (en) * 2011-07-20 2016-07-19 The General Hospital Corporation Methods and compounds for reducing intracellular lipid storage
WO2014014530A1 (en) 2012-07-17 2014-01-23 Mylari Banavara L Ursolic acid salts for treating diabetes and obesity
US9211298B2 (en) * 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
AU2015256178B2 (en) * 2014-05-05 2020-02-27 The Board Of Regents Of The University Of Texas System Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
KR20250008786A (ko) * 2014-07-29 2025-01-15 센젠 하이타이드 바이오파마슈티컬 리미티드 베르베린 염, 우르소데옥시콜산 염 및 병용물, 이들의 제조 및 응용 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JUNCO, JJ et al., "Resveratrol and P-glycoprotein Inhibitors Enhance the Anti-skin Cancer Effects of Ursolic Acid.", Molecular Cancer Research, (2013-12), vol. 11, no. 12., ISSN 1541-7786, pages 1 - 17 *
MACARULLA M T ET AL, "Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet.", JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY DEC 2009, (2009-12), vol. 65, no. 4, ISSN 1138-7548, pages 369 - 376 *
STEVEN D. KUNKEL ET AL, PLOS ONE, (2012-06-20), vol. 7, no. 6, doi:10.1371/journal.pone.0039332, page e39332 *

Also Published As

Publication number Publication date
US20190192537A1 (en) 2019-06-27
US11166962B2 (en) 2021-11-09
US20220023241A1 (en) 2022-01-27
US20170056414A1 (en) 2017-03-02
AU2020203419A1 (en) 2020-06-11
US10155003B2 (en) 2018-12-18
EP3139910B1 (en) 2019-11-27
US20210252016A1 (en) 2021-08-19
EP3139910A4 (en) 2017-11-29
US20220226347A1 (en) 2022-07-21
WO2015171598A1 (en) 2015-11-12
US20200330480A1 (en) 2020-10-22
JP2020147590A (ja) 2020-09-17
US10583145B2 (en) 2020-03-10
US11090311B2 (en) 2021-08-17
US20200323879A1 (en) 2020-10-15
EP3139910A1 (en) 2017-03-15
JP2017514858A (ja) 2017-06-08
JP6716468B2 (ja) 2020-07-01
MY181685A (en) 2020-12-31
US11642354B2 (en) 2023-05-09
US11684626B2 (en) 2023-06-27
AU2020203419B2 (en) 2021-05-13
US11690851B2 (en) 2023-07-04
AU2015256178A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
US11684626B2 (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
Calvano et al. Dietary berries, insulin resistance and type 2 diabetes: An overview of human feeding trials
Verma et al. Obesity and diabetes: an update
Fan et al. HDAC11 deletion reduces fructose-induced cardiac dyslipidemia, apoptosis and inflammation by attenuating oxidative stress injury
US20240325410A1 (en) Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
US20250000878A1 (en) Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
Rafe et al. Preventive role of resveratrol against inflammatory cytokines and related diseases
Sharma et al. Anti-diabetic effects of blue honeyberry on high-fed-diet-induced type II diabetic mouse
Yamashita et al. Cacao liquor procyanidins prevent postprandial hyperglycaemia by increasing glucagon-like peptide-1 activity and AMP-activated protein kinase in mice
US20240358055A1 (en) Dietary supplements for weight management and glycemic control
Noori et al. Role of natural mTOR inhibitors in treatment of diabetes mellitus
US20140148399A1 (en) Compositions and methods for treating or ameliorating obesity or for reducing diabetic hypercholesterolemia
US20250205263A1 (en) Oral composition comprising b-escin and the use thereof
Thapa et al. Bioactive Phytoconstituents Targeting Energy Expenditure and Appetite to Combat Obesity: A Comprehensive Review
Landrier et al. Tomatoes and lycopene: inflammatory modulator effects
Jain et al. Nutraceuticals and Obesity: Strategies for Weight Management
Anshul Sharma et al. Anti-diabetic effects of blue honeyberry on high-fed-diet-induced type II diabetic mouse.
Hastings The Effects of Estrogenic Compounds on Adipogenesis Via PPARγ and Canonical Wnt Signaling
Li EFFECTS OF GRAPE POMACE ON METABOLIC SYNDROME: DIABETES AND OBESITY
Stahel Effects of selenized casein and carbohydrate components of milk on insulin sensitivity in rats
Cyclophosphamide-Induced Poster Communications
CN112584825A (zh) 包含甲基磺酰甲烷的用于预防或改善肥胖、脂肪肝及糖尿病的组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 05 MAY 2021 TO 05 DEC 2021 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 05 DEC 2021

MK14 Patent ceased section 143(a) (annual fees not paid) or expired